ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,751.07
      0.90%
      US Tech 100
      19,476.00
      1.10%
      Dow Jones
      42,352.75
      0.81%
      Brent Oil
      77.675
      0.38%
      Bitcoin
      63,599.43
      1.25%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. iTeos Therapeutics Inc (ITOS) Quote

      iTeos Therapeutics Inc

      iTeos Therapeutics Inc (ITOS)

      NASDAQ
      10.02
      0.335
      (3.46%)
      Closed October 07 4:00PM
      Delayed by 15 minutes
      9.95
      -0.07
      (-0.70%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      10.02
      Bid
      9.80
      Ask
      10.10
      Volume
      445,192
      9.59 Day's Range 10.075
      8.20 52 Week Range 18.75
      Market Cap
      365.949M
      Previous Close
      9.685
      Open
      9.61
      Last Trade
      35
      @
      10.1135
      Last Trade Time
      Financial Volume
      $ 4,384,854
      VWAP
      9.8494
      Average Volume (3m)
      531,849
      Shares Outstanding
      36,521,845
      Dividend Yield
      -
      PE Ratio
      -3.25
      Earnings Per Share (EPS)
      -3.08
      Revenue
      12.6M
      Net Profit
      -112.64M

      About iTeos Therapeutics Inc

      ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoin... ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.iteostherapeutics.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      iTeos Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker ITOS. The last closing price for iTeos Therapeutics was $9.69. Over the last year, iTeos Therapeutics shares have traded in a share price range of $ 8.20 to $ 18.75.

      iTeos Therapeutics currently has 36,521,845 shares outstanding. The market capitalization of iTeos Therapeutics is $353.71 million. iTeos Therapeutics has a price to earnings ratio (PE ratio) of -3.25.

      Ask ADVFN Intelligence (AI)

      iTeos Therapeutics (ITOS) Options Flow Summary

      ITOS Options Flow

      Overall Flow

      Bearish

      Net Premium

      -83k

      Calls / Puts

      0.00%

      Buys / Sells

      100.00%

      OTM / ITM

      0.00%

      Sweeps Ratio

      0.00%

      ITOS Latest News

      More News

      Form 8-K - Current report

      September 16 2024
      Edgar (US Regulatory)

      iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

      - Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose- >30% cORR difference...

      September 14 2024
      GlobeNewswire Inc.

      iTeos to Participate in Upcoming Investor Conferences

      WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

      August 28 2024
      GlobeNewswire Inc.

      iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024

      WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

      August 20 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 09 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 08 2024
      Edgar (US Regulatory)

      iTeos Reports Second Quarter 2024 Financial Results and Provides Business Updates

      - Multiple clinical milestones across portfolio anticipated in second half of 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- Pro forma cash and...

      August 08 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 05 2024
      Edgar (US Regulatory)

      Form 3 - Initial statement of beneficial ownership of securities

      August 05 2024
      Edgar (US Regulatory)

      iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

      WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery...

      August 05 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.17-1.6683022571110.1910.939.6258140810.02486523CS
      4-5.51-35.479716677415.5317.639.62101706612.45074435CS
      12-6.28-38.52760736216.318.139.6253184913.82685262CS
      26-3.1-23.628048780513.1218.759.6247048414.58325233CS
      52-0.49-4.66222645110.5118.758.242781412.67822975CS
      156-16.82-62.667660208626.8452.438.238611919.76864591CS
      260-9.68-49.137055837619.752.438.235109421.45823232CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      CHSNChanson International Holding
      $ 11.22
      (269.08%)
      		14.76M
      PEVPhoenix Motor Inc
      $ 1.0607
      (205.24%)
      		228.42M
      ENTOEntero Therapeutics Inc
      $ 0.60
      (72.20%)
      		10.42M
      BENFBeneficient
      $ 1.8914
      (58.94%)
      		108.31M
      FORDForward Industries Inc
      $ 5.3254
      (52.15%)
      		18.45M
      ADDColor Star Technology Company Ltd
      $ 0.2701
      (-39.98%)
      		15.01M
      DUOFangDD Network Group Ltd
      $ 2.53
      (-32.89%)
      		28.52M
      ICCTiCoreConnect Inc
      $ 0.4102
      (-31.50%)
      		1.68M
      ZENAZenaTech Inc
      $ 3.91
      (-29.55%)
      		213.24k
      SPAISafe Pro Group Inc
      $ 1.93
      (-25.77%)
      		239.89k
      NVDANVIDIA Corporation
      $ 124.92
      (1.68%)
      		244.46M
      PEVPhoenix Motor Inc
      $ 1.0607
      (205.24%)
      		228.42M
      SQQQProShares UltraPro Short QQQ
      $ 7.43
      (-3.63%)
      		184.47M
      NCNCnoco noco Inc
      $ 0.144
      (8.60%)
      		147.38M
      BENFBeneficient
      $ 1.8914
      (58.94%)
      		108.31M

      ITOS Discussion

      View Posts
      Monksdream Monksdream 3 weeks ago
      ITOS needs to break $19
      👍️0
      Awl416 Awl416 5 months ago
      iTeos Therapeutics Announces $120 Million Registered Direct Offering
      👍️0
      TonyJoe1957 TonyJoe1957 3 years ago
      $14.41 EPS estimate for 3rd quarter posted today on TDAmeritrade.
      👍️0
      TonyJoe1957 TonyJoe1957 3 years ago
      https://seekingalpha.com/article/4449555-iteos-therapeutics-my-calculations-suggest-q3-earnings-will-exceed-10-per-share
      👍️0
      TonyJoe1957 TonyJoe1957 3 years ago
      Wow!
      No one posting or interested in this stock?
      👍️0
      TonyJoe1957 TonyJoe1957 3 years ago
      Note the intraday lows for the past 3 trading days. Program trading walking it down to $25.60, $25.30 and $25.25. Stay well. AJ
      👍️0
      TonyJoe1957 TonyJoe1957 3 years ago
      I think we are trading below cash per share.
      👍️0
      ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 3 years ago
      ITOS $28.50 gonna be wild in little after $30
      👍️0
      ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 3 years ago
      Itos will break $30 and game on,holding here
      👍️0
      ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 3 years ago
      ITOS~~$28.11
      👍️0
      ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 3 years ago
      ITOS~~MA200,@ $28.75,should break today here
      👍️0
      TonyJoe1957 TonyJoe1957 3 years ago
      Bought 580 sh, so far.
      5 analysts at 8:30A webcast.
      All congratulated the firm on the deal.
      I anticipate an easy double in the next few months with upgrades.
      Look at the balance sheet.
      Really, really big cash infusion.
      AJ
      👍️0
      ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 3 years ago
      ITOS~~bought 809 shares @$33pm,little high on spike ,but should go nicely up,crazy huge news
      👍️0
      $treet $inatra $treet $inatra 4 years ago
      https://investors.iteostherapeutics.com/news-and-events/press-releases


      👍️0

      Your Recent History

      NASDAQ
      ITOS
      iTeos Therapeutics
      Delayed Upgrade Clock